Copanlisib (BAY 80-6946) is a potent, selective, and ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM for PI3Kα, 0.7 nM for PI3Kδ, 3.7 nM for PI3Kβ, and 6.4 nM for PI3Kγ). It exhibits over 2,000-fold selectivity against other kinases, except for mTOR, and demonstrates strong antitumor activity by inhibiting PI3K signaling and inducing tumor regression. Reagent grade, for research purpose.
Usually ships within 24 hours.